- Tafenoquine
-
- $193.00 / 5mg
-
2024-10-28
- CAS:106635-80-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Tafenoquine Basic information |
| Product Name: | Tafenoquine | | Synonyms: | Tafenoquine;4-[5-[3-(Trifluoromethyl)phenoxy]-2,6-dimethoxy-4-methyl-8-quinolinylamino]-1-pentanamine;8-[(4-Amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinoline;N4-(2,6-diMethoxy-4-Methyl-5-(3-(trifluoroMethyl)phenoxy)quinolin-8-yl)pentane-1,4-diaMine;N4-{2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl}-1,4-pentanediamine;WR 238605; WR238605; WR-238605; SB-252263; SB 252263; SB252263;WR-238605, WR 238605, WR238605, SB-252263-AAB; SB252263-AAB; SB 252263-AAB; TAFENOQUINE; KRINTAFE;Krintafe | | CAS: | 106635-80-7 | | MF: | C24H28F3N3O3 | | MW: | 463.49 | | EINECS: | | | Product Categories: | | | Mol File: | 106635-80-7.mol |  |
| | Tafenoquine Chemical Properties |
| Melting point | 60 - 63°C | | Boiling point | 565.6±50.0 °C(Predicted) | | density | 1.237±0.06 g/cm3(Predicted) | | storage temp. | 4°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 10.36±0.10(Predicted) | | form | Solid | | color | Dark Orange to Very Dark Orange |
| | Tafenoquine Usage And Synthesis |
| Uses | Tafenoquine is a pharmaceutical developed for the treatment of Plasmodium vivax malaria. Tafenoquine is also being explored for pharmaceutical use for inhibition of Toxoplasma gondii growth. | | Definition | ChEBI: N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine is an aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group. It is a member of (trifluoromethyl)benzenes, an aminoquinoline, an aromatic ether, a primary amino compound and a secondary amino compound. | | Pharmaceutical Applications | Etaquine. A synthetic 8-aminoquinoline, formulated as the
succinate for oral administration. Tafenoquine is an effective
schizonticide against P. falciparum and P. vivax. It is also
active against the pre-erythrocytic stages of these species and
the hypnozoites of P. vivax. A dosage of 100 mg base corresponds
to 125 mg salt. Oral absorption is slow with a maximum
plasma concentration reached after 12 h. The half-life is
2 weeks, significantly longer than that of primaquine. It is not
eliminated via the kidneys. Toxicity and side effects are similar
to those of primaquine. Development of methemoglobinemia
is common. Patients with G6PD deficiency may develop
severe hemolysis.
It is in clinical development for the treatment and prophylaxis
of P. vivax malaria and for the treatment of P. falciparum
infection. |
| | Tafenoquine Preparation Products And Raw materials |
|